{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:12:12Z","timestamp":1790154732030,"version":"4.0.1"},"reference-count":36,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T00:00:00Z","timestamp":1489968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Nonsteroidal anti\u2010inflammatory drugs (\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      s) are the most frequent triggers of drug hypersensitivity with\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      s\u2010induced urticaria\/angioedema (\n                      <jats:styled-content style=\"fixed-case\">NIUA<\/jats:styled-content>\n                      ) the most common phenotype. Loss of hypersensitivity has been reported for IgE\u2010mediated reactions; however, it has not been assessed in nonimmunological reactions such as\n                      <jats:styled-content style=\"fixed-case\">NIUA<\/jats:styled-content>\n                      . We evaluated\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      \u2010hypersensitivity over time in\n                      <jats:styled-content style=\"fixed-case\">NIUA<\/jats:styled-content>\n                      patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients confirmed as\n                      <jats:styled-content style=\"fixed-case\">NIUA<\/jats:styled-content>\n                      by positive drug provocation test (\n                      <jats:styled-content style=\"fixed-case\">DPT<\/jats:styled-content>\n                      ) with acetylsalicylic acid (\n                      <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>\n                      ) during 2005\u20102012 (V1) were included (n=38). Subjects were prospectively re\u2010evaluated by\n                      <jats:styled-content style=\"fixed-case\">DPT<\/jats:styled-content>\n                      with\n                      <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>\n                      \/other\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      s at two time points between 2013 and 2015 (V2 and V3). Atopy was assessed by skin prick test (\n                      <jats:styled-content style=\"fixed-case\">SPT<\/jats:styled-content>\n                      ) using inhalant and food allergens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients were evaluated at V1 and re\u2010evaluated after 60 months (V2;\n                      <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>\n                      :48\u201081) and a further 18 months (V3;\n                      <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>\n                      :14\u201024). At V2, the majority (24; 63.15%) tolerated\n                      <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>\n                      and other\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      s (Group A) while 14 (36.84%) still reacted (Group B). At V3, all Group A patients remained tolerant; all Group B patients remained hypersensitive. The number of previous episodes reported at V1 and the percentage of reactions induced by\n                      <jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>\n                      \/ibuprofen were significantly lower in Group A (\n                      <jats:italic>P<\/jats:italic>\n                      =.005 and\n                      <jats:italic>P<\/jats:italic>\n                      =.006, respectively). Group A patients developed tolerance 72 months (\n                      <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>\n                      :45\u201087) after their last evaluated reaction (V1); this interval was shorter in nonatopics (\n                      <jats:italic>P<\/jats:italic>\n                      =.003), patients who experienced reactions over 1 hour after\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      s administration (\n                      <jats:italic>P<\/jats:italic>\n                      =.001), and those who experienced isolated urticaria after\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      intake (\n                      <jats:italic>P<\/jats:italic>\n                      =.024).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:styled-content style=\"fixed-case\">NIUA<\/jats:styled-content>\n                      patients may develop tolerance to\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      s over time, a process that seems to be influenced by atopy and type of clinical reaction.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/all.13147","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T18:06:43Z","timestamp":1487786803000},"page":"1346-1355","source":"Crossref","is-referenced-by-count":51,"title":["Natural evolution in patients with nonsteroidal anti\u2010inflammatory drug\u2010induced urticaria\/angioedema"],"prefix":"10.1111","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-4878","authenticated-orcid":false,"given":"I.","family":"Do\u00f1a","sequence":"first","affiliation":[{"name":"Allergy Unit Regional University Hospital of Malaga\u2010IBIMA Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Barrionuevo","sequence":"additional","affiliation":[{"name":"Allergy Unit Regional University Hospital of Malaga\u2010IBIMA Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salas","sequence":"additional","affiliation":[{"name":"Allergy Unit Regional University Hospital of Malaga\u2010IBIMA Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Cornejo\u2010Garc\u00eda","sequence":"additional","affiliation":[{"name":"Research Laboratory IBIMA\u2010Regional University Hospital of Malaga\u2010UMA Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Perkins","sequence":"additional","affiliation":[{"name":"Research Laboratory IBIMA\u2010Regional University Hospital of Malaga\u2010UMA Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bogas","sequence":"additional","affiliation":[{"name":"Allergy Unit Regional University Hospital of Malaga\u2010IBIMA Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prieto","sequence":"additional","affiliation":[{"name":"Allergy Unit Regional University Hospital of Malaga\u2010IBIMA Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Torres","sequence":"additional","affiliation":[{"name":"Allergy Unit Regional University Hospital of Malaga\u2010IBIMA Malaga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2004.02070.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-12-200406150-00009"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12260"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32832db943"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1081\/IPH-100108604"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2010.03651.x"},{"key":"e_1_2_8_8_1","first-page":"363","article-title":"Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients","volume":"22","author":"Do\u00f1a I","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12039"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-0969"},{"key":"e_1_2_8_11_1","first-page":"114","article-title":"Nonsteroidal anti\u2010inflammatory drug hypersensitivity in preschool children","volume":"3","author":"Kidon MI","year":"2007","journal-title":"Allergy Asthma Clin Immunol"},{"key":"e_1_2_8_12_1","first-page":"277","article-title":"NSAID facial angioedema in a selected pediatric atopic population","volume":"10","author":"Capriles\u2010Behrens E","year":"2000","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1444"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12335"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01713.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03237.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.09.005"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01409.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03774.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.00978.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(76)90102-0"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1487"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63146-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70102-1"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62748-2"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60526-1"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1688-x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85538"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000178"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.12.003"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00299"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12013"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2010.03648.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.5.e53"},{"key":"e_1_2_8_35_1","volume-title":"Analgesic Antipyretic and Inflammatory Agents and Drugs Employed In The Treatment of Gout","author":"Roberts LJMJ","year":"2011"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2010.04.006"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2263-6"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fall.13147","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.13147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T21:55:06Z","timestamp":1694987706000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.13147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,20]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/all.13147"],"URL":"https:\/\/doi.org\/10.1111\/all.13147","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727331592.793529256","asserted-by":"object"}]},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,20]]}}}